Antineoplastic drug induced nausea and vomiting: What is the clinical practice in 2018? An update of AFSOS clinical guidelines

Titre traduit de la contribution: Nausées-vomissements induits par les traitements anti-cancéreux (NVITAC): quelle prise en charge en 2018 ? Mise à jour du référentiel AFSOS

Groupe de travail du référentiel Association francophone pour les soins oncologiques de support (AFSOS) sur les nausées-vomissements induits par les traitements anti-cancéreux

Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

10 Citations (Scopus)

Résumé

Antineoplastic drug induced nausea and vomiting (ANDINV) (previously named: Chemotherapy-induced nausea and vomiting [CINV]) are one of the most feared adverse effect for patients who begin treatment with anti-cancer treatments and their bad control have a negative impact in the management of these patients. In this review article, it is proposed an update of French-speaking Association for oncologic supportive care (AFSOS) clinical practice of CINV guidelines. This update became necessary for several reasons: newly available anti–emetic drugs; new data published about individual risk factors of CINV; new antineoplastic agents available; changing in emetic risk levels for some molecules in the international guidelines. To address these guidelines, the various clinical presentations of ANDINV and their intensity classification are discussed. Then, the different therapeutic solutions are presented: classes of conventional drug therapies, complementary therapies and advice to patients. Then, the implementation of primary prophylaxis are presented in four steps: (1) to evaluate the emetic risk level of antineoplastic agent; (2) to set the emetic risk level of antineoplastic protocols; (3) to set types of antiemetic drugs to implement; (4) “Outperform” prophylaxis in case of individual risk factors. Finally, implementation of secondary prophylaxis and rescue treatments are adressed.

Titre traduit de la contributionNausées-vomissements induits par les traitements anti-cancéreux (NVITAC): quelle prise en charge en 2018 ? Mise à jour du référentiel AFSOS
langue originaleAnglais
Pages (de - à)497-509
Nombre de pages13
journalBulletin du Cancer
Volume106
Numéro de publication5
Les DOIs
étatPublié - 1 mai 2019
Modification externeOui

Contient cette citation